DelveInsight's Chronic Refractory Cough Market Insights report includes a comprehensive understanding of current treatment practices, emerging chronic refractory cough drugs, market share of ...

Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...

While chronic cough lasting more than 8 weeks is frequently encountered in outpatient settings, clinicians often struggle ...

Please provide your email address to receive an email when new articles are posted on . There are no approved treatments, so providers use off-label prescriptions. 30.4% did not know the three most ...

Please provide your email address to receive an email when new articles are posted on . These results, published in JAMA in conjunction with a presentation at the European Respiratory Society ...

Topline results are expected in the first quarter of 2025 The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with ...

Chronic cough, defined as a cough lasting at least 8 weeks, affects approximately 5% of the European population, particularly older adults and individuals with a history of smoking. In some cases, ...

Patients with unexplained or refractory chronic cough (URCC) experienced nearly double the rate of depressive symptoms compared with control individuals without chronic cough, along with a more than ...

Chronic cough is undergoing a pivotal shift—from being viewed merely as a symptom to being recognized as a distinct disease entity. From December 4 to 6, 2025, the 5th International Cough Conference ...

Pharma giant GlaxoSmithKline on Tuesday announced a deal to buy Canadian biotech Bellus Health for $2 billion, betting big on the firm’s cough medicine as it moves to shore up its slender drug ...

Daily treatment with SC0023 yielded treatment efficacy 53.5% ± 19.2% relative to baseline in 24-hour daily cough rate and 19.5% ± 6.2% placebo effect Cough rate reduction was observed from the first ...